Several experimental and epidemiological studies have suggested that insulin therapy could produce a substantial increase in the risk of cancer in patients with type 2 diabetes, partly explaining differences in incidence with respect to nondiabetic subjects. The gene discussed is INS; the disease is type 2 diabetes mellitus.